Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenacapavir + optimized background regimen
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Lenacapavir in combination with an optimized background regimen (OBR) is a therapeutic approach developed by Gilead Sciences for the treatment of multi-drug resistant HIV-1 infection. Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor that disrupts the viral lifecycle at multiple stages, including capsid-mediated nuclear uptake of viral DNA, virus assembly and release, and capsid core formation. The optimized background regimen (OBR) consists of a personalized combination of antiretroviral agents (such as NRTIs, NNRTIs, PIs, or INSTIs) selected by a clinician based on the patient's specific viral resistance profile and treatment history. This combination is particularly indicated for heavily treatment-experienced (HTE) patients, including adults, adolescents, and children, who have limited treatment options due to extensive drug resistance.
- Other names
- LEN + OBROptimized Background RegimenOBR
02
Targets
p24 (HIV-1 capsid protein p24)Integrase allosteric pocket (HIV)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on lenacapavir + optimized background regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenacapavir + optimized background regimen.